OLMA - Olema Pharmaceuticals, Inc.
Price:
--
--
|
CONSENSUS:
Buy
DETAILS
|
PRICE TARGET:
$41.88
DETAILS
HIGH:
$48.00
LOW:
$35.00
MEDIAN:
$41.50
CONSENSUS:
$41.88
UPSIDE:
206.14%
About Olema Pharmaceuticals, Inc. (https://www.olema.com)
Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer. The company was formerly known as CombiThera, Inc. and changed its name to Olema Pharmaceuticals, Inc. in March 2009. Olema Pharmaceuticals, Inc. was incorporated in 2006 and is headquartered in San Francisco, California.
Key Executives
| NAME | TITLE | DOB | SALARY |
|---|---|---|---|
| Sean Bohen | President, CEO, Interim Principal Financial Officer & Director | 1967 | $1,176,990 USD |
| Shane William Charles Kovacs | Consultant | 1974 | $902,735 USD |
| Naseem Zojwalla | Chief Medical Officer | 1973 | $777,970 USD |
| Shawnte Mitchell | Chief Legal Officer & Corporate Secretary | 1978 | $664,750 USD |
| David C. Myles | Chief Scientific Officer | 1963 | $200,000 USD |
| Angelos Dovletoglou | Senior Vice President of CMC & Supply Chain | – | – |
| Courtney O'Konek | Vice President of Corporate Communications | – | – |
| Julie Dexter | Senior Vice President & Head of People | – | – |
| Kamesh Kuchimanchi | Senior Vice President of Regulatory Affairs & Quality Assurance | – | – |
| Mark Shilkrut | Senior Vice President of Clinical Development | – | – |
| Meghna Chowdary | Senior Vice President of Commercial Strategy & Operations | – | – |
| Richard Hernandez | Senior Vice President of Clinical Development Operations | – | – |
| Sasha Austin | Vice President of Finance & Controller | – | – |